ClinicalTrials.gg
CompletedNCT02637037Updated Mar 13, 2018Results posted

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

A Phase 1 interventional study of dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon) and dapagliflozin/metformin XR 5/500 mg reference drug (Humacao) in Bioequivalence, Fixed Dose Combination Tablets and Healthy Male and Female Subjects, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-13.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca — 13 open to participants now, 15 under way, 9 of them phase 3. Diabetes Mellitus, Type 2 · AstraZeneca.

Enrollment
168th of 280
80 · median 155
Started
2015
with 14 others
Phase 1
86 of 345
2 open now
Registered
257th of 345
by date

Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 168th largest by enrollment of the 280 interventional ones that give a count, is one of 15 that started in 2015, is one of 86 in phase 1, and was the 257th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

13 of the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, or all of them as a file.
02

Study summary

This is a bioequivalence study to compare 2 fixed-dose combination tablets of dapagliflozin/metformin XR manufactured at 2 different plants in healthy subjects under fasting and fed conditions

Read the detailed description

This is a Phase 1, 2-part, open-label, randomized, 4-period, 4-treatment, crossover study in healthy subjects (males and females of non-childbearing potential)

03

Conditions studied

  • Bioequivalence
  • Fixed Dose Combination Tablets
  • Healthy Male and Female Subjects

Keywords

  • dapagliflozin/metformin XR 5/500 mg
  • dapagliflozin/metformin XR10/1000 mg
  • bioequivalence
  • fixed dose combination tablets
  • pharmacokinetic
  • type 2 Diabetes Mellitus (T2DM)
  • safety
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written prior to any study specific procedures
  2. Healthy male and female subjects aged 18 - 55 years with suitable veins for cannulation or repeated venipuncture
  3. Females must have a negative serum pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-, confirmed at screening by fulfilling 1 of the following criteria:

    • defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle-stimulating hormone (FSH) levels in the post-menopausal range
    • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation
  4. Have a (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive at screening

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
  2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
  3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of medicinal product
  4. Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the investigator
  5. Any clinically significant abnormal findings in vital signs, as judged by the investigator
  6. Any clinically significant abnormalities on 12-lead as judged by the investigator
  7. Any positive result on screening for serum surface antigen (HBsAg), antibody and (HIV) antibody
  8. Known or suspected history of drug abuse, as judged by the investigator
  9. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose.
  10. Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening
  11. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to dapagliflozin/metformin XR.
  12. Current smokers or those who have smoked or used nicotine products within the 3 months prior to screening
  13. Positive screen for drugs of abuse, cotinine or alcohol at screening or on each admission to the study center
  14. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP
  15. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, vitamins and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life
  16. Known or suspected history of alcohol abuse or excessive intake of alcohol as judged by the investigator
  17. Involvement of any AstraZeneca or study site employee or their close relatives
  18. Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements
  19. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Treatment A

    Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose

    Drug: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)

  • Active comparator
    Treatment B

    Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose

    Drug: dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)

  • Experimental
    Treatment C

    Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose

    Drug: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)

  • Active comparator
    Treatment D

    Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose

    Drug: dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)

  • Experimental
    Treatment E

    Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose

    Drug: dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)

  • Active comparator
    Treatment F

    Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose

    Drug: dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)

  • Experimental
    Treatment G

    Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose

    Drug: dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)

  • Active comparator
    Treatment H

    Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose

    Drug: dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)

Interventions

  • Drugdapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)

    single fixed-combination dose tablets

  • Drugdapagliflozin/metformin XR 5/500 mg reference drug (Humacao)

    single fixed-dose combination tablets

  • Drugdapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)

    single fixed-dose combination tablets

  • Drugdapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)

    single fixed-dose combination tablets

06

What researchers measure

Primary outcomes

  1. Area Under Plasma Concentration-time Curve [AUC] Under Fasted or Fed State

    To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state.

    Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period

  2. AUC From Time Zero to Time of Last Quantifiable Concentration [AUC (0-t)] Under Fasted or Fed State.

    To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state

    Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period

  3. Observed Maximum Plasma Concentration [Cmax] Under Fasted or Fed State

    To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state

    Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period

Secondary outcomes

  1. Time to Reach Maximum Plasma Concentration (t Max)

    To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.

    Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period

  2. Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve [t½λz]

    To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.

    Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period

  3. Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC [CL/F]

    To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.

    Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period

  4. Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration [Vz/F]

    To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.

    Time frame: Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period

07

Results

Posted Mar 13, 2018

Participant flow

This study was conducted at PAREXEL International, Early Phase Clinical Unit Baltimore, United States of America. Subjects were randomized into 4-period, 4-treatment (per study part) crossover (4 sequences containing 4 treatments) in fed and fasted state.

Participant flow — Overall Study
MilestonePart 1Part 2
Started4040
Completed3639
Not completed41
Withdrew: Positive drug screen at admission10
Withdrew: Withdrawal by subject21
Withdrew: Adverse event10

Outcome measures

PrimaryArea Under Plasma Concentration-time Curve [AUC] Under Fasted or Fed State

To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state.

Time frame:
Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
Reported as:
Geometric mean · h*ng/mL
Area Under Plasma Concentration-time Curve [AUC] Under Fasted or Fed State
h*ng/mLTreatment ATreatment BTreatment CTreatment DTreatment ETreatment FTreatment GTreatment H
Dapagliflozin236.3 ± 21.06248.6 ± 20.79251.6 ± 21.20258.2 ± 18.35471.9 ± 27.46486.9 ± 26.47504.4 ± 27.22516.6 ± 27.15
Metformin5484 ± 24.695465 ± 27.874398 ± 29.414460 ± 29.698403 ± 27.908015 ± 31.657727 ± 30.827578 ± 35.76
Statistical analysis
  • Treatment A vs Treatment B · Ratios of geometric means: 0.96 · 90% CI 0.93 to 0.99
  • Treatment C vs Treatment D · Ratios of geometric means: 0.99 · 90% CI 0.96 to 1.01
  • Treatment E vs Treatment F · Ratios of geometric means: 0.97 · 90% CI 0.94 to 1.00
  • Treatment G vs Treatment H · Ratios of geometric means: 0.98 · 90% CI 0.95 to 1.00
  • Treatment A vs Treatment B · Ratios of geometric means: 1.01 · 90% CI 0.96 to 1.06
  • Treatment C vs Treatment D · Ratios of geometric means: 1.00 · 90% CI 0.93 to 1.07
  • Treatment E vs Treatment F · Ratios of geometric means: 1.05 · 90% CI 0.99 to 1.11
  • Treatment G vs Treatment H · Ratios of geometric means: 1.03 · 90% CI 0.96 to 1.10
PrimaryAUC From Time Zero to Time of Last Quantifiable Concentration [AUC (0-t)] Under Fasted or Fed State.

To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state

Time frame:
Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
Reported as:
Geometric mean · h*ng/mL
AUC From Time Zero to Time of Last Quantifiable Concentration [AUC (0-t)] Under Fasted or Fed State.
h*ng/mLTreatment ATreatment BTreatment CTreatment DTreatment ETreatment FTreatment GTreatment H
Dapagliflozin228.1 ± 20.43239.1 ± 21.10243.4 ± 20.93248.8 ± 17.92454.7 ± 27.15472.1 ± 26.72490.9 ± 27.30505.1 ± 26.80
Metformin5307 ± 26.545205 ± 28.594211 ± 28.714212 ± 27.228040 ± 27.827798 ± 32.777456 ± 30.577401 ± 34.75
Statistical analysis
  • Treatment A vs Treatment B · Ratios of geometric means: 0.96 · 90% CI 0.94 to 0.99
  • Treatment C vs Treatment D · Ratios of geometric means: 0.99 · 90% CI 0.97 to 1.02
  • Treatment E vs Treatment F · Ratios of geometric means: 0.96 · 90% CI 0.93 to 0.98
  • Treatment G vs Treatment H · Ratios of geometric means: 0.97 · 90% CI 0.95 to 1.00
  • Treatment A vs Treatment B · Ratios of geometric means: 1.02 · 90% CI 0.97 to 1.08
  • Treatment C vs Treatment D · Ratios of geometric means: 1.01 · 90% CI 0.95 to 1.06
  • Treatment E vs Treatment F · Ratios of geometric means: 1.03 · 90% CI 0.97 to 1.09
  • Treatment G vs Treatment H · Ratios of geometric means: 1.01 · 90% CI 0.95 to 1.07
PrimaryObserved Maximum Plasma Concentration [Cmax] Under Fasted or Fed State

To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state

Time frame:
Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
Reported as:
Geometric mean · ng/mL
Observed Maximum Plasma Concentration [Cmax] Under Fasted or Fed State
ng/mLTreatment ATreatment BTreatment CTreatment DTreatment ETreatment FTreatment GTreatment H
Dapagliflozin39.69 ± 26.4241.33 ± 18.4965.28 ± 25.4967.41 ± 24.9587.48 ± 30.1490.14 ± 32.09125.6 ± 30.77132.7 ± 28.31
Metformin510.2 ± 22.23503.4 ± 22.16563.2 ± 30.27573.9 ± 28.55982.6 ± 28.11975.5 ± 27.891016 ± 35.36998.5 ± 36.05
Statistical analysis
  • Treatment A vs Treatment B · Ratios of geometric means: 0.98 · 90% CI 0.93 to 1.03
  • Treatment C vs Treatment D · Ratios of geometric means: 0.97 · 90% CI 0.90 to 1.06
  • Treatment E vs Treatment F · Ratios of geometric means: 0.97 · 90% CI 0.89 to 1.05
  • Treatment G vs Treatment H · Ratios of geometric means: 0.95 · 90% CI 0.87 to 1.03
  • Treatment A vs Treatment B · Ratios of geometric means: 1.01 · 90% CI 0.96 to 1.07
  • Treatment C vs Treatment D · Ratios of geometric means: 0.98 · 90% CI 0.92 to 1.04
  • Treatment E vs Treatment F · Ratios of geometric means: 1.00 · 90% CI 0.95 to 1.06
  • Treatment G vs Treatment H · Ratios of geometric means: 1.02 · 90% CI 0.94 to 1.10
SecondaryTime to Reach Maximum Plasma Concentration (t Max)

To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.

Time frame:
Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
Reported as:
Median · Hour
Time to Reach Maximum Plasma Concentration (t Max)
HourTreatment ATreatment BTreatment CTreatment DTreatment ETreatment FTreatment GTreatment H
Dapagliflozin2.50 (1.00 to 4.00)3.00 (1.00 to 4.00)1.00 (0.50 to 2.98)1.00 (0.48 to 2.92)2.00 (0.98 to 4.00)2.00 (0.98 to 4.00)1.00 (0.50 to 1.98)1.00 (0.48 to 3.00)
Metformin6.00 (4.00 to 11.95)6.00 (3.98 to 12.03)4.00 (2.00 to 6.00)4.00 (2.00 to 6.03)4.00 (3.98 to 7.98)4.00 (3.98 to 6.02)4.00 (1.00 to 6.00)4.00 (1.98 to 6.00)
SecondaryHalf-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve [t½λz]

To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.

Time frame:
Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
Reported as:
Mean · Hour (h)
Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve [t½λz]
Hour (h)Treatment ATreatment BTreatment CTreatment DTreatment ETreatment FTreatment GTreatment H
Dapagliflozin14.01 ± 6.74714.65 ± 7.24513.73 ± 6.20316.55 ± 8.26014.88 ± 6.27214.42 ± 5.77814.72 ± 5.64115.11 ± 5.998
Metformin13.48 ± 7.87312.87 ± 6.58711.91 ± 7.35113.52 ± 8.76014.18 ± 7.71813.74 ± 6.98414.38 ± 8.24115.94 ± 9.671
SecondaryApparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC [CL/F]

To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.

Time frame:
Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
Reported as:
Mean · L/h
Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC [CL/F]
L/hTreatment ATreatment BTreatment CTreatment DTreatment ETreatment FTreatment GTreatment H
Dapagliflozin421.3 ± 194.2424.4 ± 217.3412.7 ± 220.5454.6 ± 202.6476.5 ± 224433.3 ± 196.1441.7 ± 191.7421.4 ± 163.1
Metformin2030 ± 14072133 ± 18912104 ± 13092803 ± 20663357 ± 25493324 ± 27133635 ± 26483212 ± 2079
SecondaryApparent Volume of Distribution During the Terminal Phase After Extravascular Administration [Vz/F]

To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.

Time frame:
Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period
Reported as:
Mean · L
Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration [Vz/F]
LTreatment ATreatment BTreatment CTreatment DTreatment ETreatment FTreatment GTreatment H
Dapagliflozin21.62 ± 4.61720.55 ± 4.50620.32 ± 4.50319.68 ± 3.65021.93 ± 5.74721.22 ± 5.58520.49 ± 5.13820.00 ± 4.974
Metformin93.78 ± 22.7194.89 ± 26.81118.1 ± 32.16116.9 ± 36.62123.5 ± 34.68130.5 ± 39.23134.9 ± 37.59140 ± 50.70

Adverse events

Collected over From screening until 72 hours postdose for each treatment period (ie. visit 1 to visit 6).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A—0/40 (0%)2/40 (5%)
Treatment B—0/38 (0%)5/38 (13.2%)
Treatment C—0/37 (0%)1/37 (2.7%)
Treatment D—0/36 (0%)2/36 (5.6%)
Treatment E—0/39 (0%)2/39 (5.1%)
Treatment F—0/40 (0%)4/40 (10%)
Treatment G—0/39 (0%)4/39 (10.3%)
Treatment H—0/39 (0%)3/39 (7.7%)
Most frequent other events
Most frequent other events
EventTreatment ATreatment BTreatment CTreatment DTreatment ETreatment FTreatment GTreatment H
HeadacheNervous system disorders1/403/380/371/362/390/400/391/39
DiarrheaGastrointestinal disorders0/402/381/371/360/392/403/392/39
FatigueGeneral disorders1/400/380/370/360/392/401/390/39

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part 1Part 2Total
Mean35.4 ± 10.3838.1 ± 9.7136.5 ± 10.04
Sex: Female, Male
Sex: Female, Male(Participants)Part 1Part 2Total
Female134
Male393776
08

Study locations

1 site
  • Research Site
    Baltimore, Maryland 21225, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Apr 2016, 3 months.

Results were first posted in Mar 2018, 1 year 11 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2015
First posted
Dec 22, 2015
StartActual
Dec 21, 2015
Primary completionActual
Apr 7, 2016
CompletionActual
Apr 7, 2016
Results first posted
Mar 13, 2018
Last update
Mar 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02637037
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 22, 2015
Start date
Dec 21, 2015
Primary completion
Apr 7, 2016
Completion
Apr 7, 2016
Results posted
Mar 13, 2018
Last update
Mar 13, 2018

Study contacts

Ronald Goldwater, MDCM, M.Sc, CPI
principal investigator · PAREXEL Early Phase Clinical Unit Baltimore

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion